Wealth Enhancement Advisory Services LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, Holdings Channel reports. The fund purchased 53,052 shares of the biopharmaceutical company’s stock, valued at approximately $3,601,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its holdings in shares of Gilead Sciences by 1.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock valued at $320,822,000 after buying an additional 51,905 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Gilead Sciences during the first quarter worth $2,305,000. CAPROCK Group Inc. increased its position in shares of Gilead Sciences by 14.2% during the first quarter. CAPROCK Group Inc. now owns 5,457 shares of the biopharmaceutical company’s stock worth $355,000 after purchasing an additional 678 shares in the last quarter. DeDora Capital Inc. increased its position in shares of Gilead Sciences by 29.9% during the first quarter. DeDora Capital Inc. now owns 14,632 shares of the biopharmaceutical company’s stock worth $951,000 after purchasing an additional 3,370 shares in the last quarter. Finally, American National Bank increased its position in shares of Gilead Sciences by 2.0% during the first quarter. American National Bank now owns 47,974 shares of the biopharmaceutical company’s stock worth $3,119,000 after purchasing an additional 929 shares in the last quarter. 78.87% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ GILD traded down $0.04 during midday trading on Thursday, reaching $63.08. 2,967,581 shares of the stock were exchanged, compared to its average volume of 6,220,770. The firm has a 50 day moving average of $66.33. The stock has a market cap of $81.03 billion, a PE ratio of 10.26, a P/E/G ratio of 3.04 and a beta of 1.16. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.14. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm’s quarterly revenue was down 2.8% on a year-over-year basis. During the same quarter last year, the company posted $1.91 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.99%. Gilead Sciences’s payout ratio is currently 40.98%.
GILD has been the topic of a number of recent analyst reports. Royal Bank of Canada raised Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price target on the stock in a research report on Monday, July 29th. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Goldman Sachs Group downgraded shares of Gilead Sciences from a “neutral” rating to a “sell” rating and cut their price objective for the company from $70.00 to $60.00 in a report on Tuesday, May 28th. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $68.00 to $88.00 in a report on Monday, July 15th. Finally, Credit Suisse Group cut their price objective on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $82.29.
In related news, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the transaction, the executive vice president now owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Strike Price
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.